The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

被引:4
作者
Li, Shu-Jing [1 ]
Liu, An-Bu [2 ]
Yu, Yuan-Yuan [2 ]
Ma, Jin-Hai [1 ]
机构
[1] Ningxia Med Univ, Gen Hosp, Dept Pediat Med, Yinchuan, Ningxia, Peoples R China
[2] Ningxia Med Univ, Gen Hosp, Dept Emergency Med, Yinchuan, Ningxia, Peoples R China
关键词
non-alcoholic fatty liver disease (NAFLD); pyroptosis; NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome; gasdermin D (GSDMD); caspase; targeted therapy; NLRP3 INFLAMMASOME ACTIVATION; HEPATOCYTE PYROPTOSIS; HEPATIC STEATOSIS; CELL-DEATH; FIBROSIS; STEATOHEPATITIS; NASH; INHIBITOR; APOPTOSIS; LIPOTOXICITY;
D O I
10.3389/fcell.2024.1407738
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
引用
收藏
页数:14
相关论文
共 50 条
[31]   Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD) [J].
Kei, Nelson ;
Wong, Vincent Wai Sun ;
Lauw, Susana ;
You, Lijun ;
Cheung, Peter Chi Keung .
FOODS, 2023, 12 (17)
[32]   Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) [J].
Rong, Li ;
Zou, Junyan ;
Ran, Wei ;
Qi, Xiaohong ;
Chen, Yaokai ;
Cui, Hongjuan ;
Guo, Jinjun .
FRONTIERS IN ENDOCRINOLOGY, 2023, 13
[33]   Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community [J].
Park, Yongsoo ;
Ko, Kyung Soo ;
Rhee, Byoung Doo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)
[34]   Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis [J].
Senavirathna, Tharani ;
Shafaei, Armaghan ;
Lareu, Ricky ;
Balmer, Lois .
ANTIOXIDANTS, 2024, 13 (04)
[35]   The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease [J].
Winarto, Jessica ;
Song, Dae-Geun ;
Pan, Cheol-Ho .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (09)
[36]   Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [J].
Burra, Patrizia ;
Bizzaro, Debora ;
Gonta, Anna ;
Shalaby, Sarah ;
Gambato, Martina ;
Morelli, Maria Cristina ;
Trapani, Silvia ;
Floreani, Annarosa ;
Marra, Fabio ;
Brunetto, Maurizia Rossana ;
Taliani, Gloria ;
Villa, Erica .
LIVER INTERNATIONAL, 2021, 41 (08) :1713-1733
[37]   Current therapeutic strategies in non-alcoholic fatty liver disease [J].
Dowman, J. K. ;
Armstrong, M. J. ;
Tomlinson, J. W. ;
Newsome, P. N. .
DIABETES OBESITY & METABOLISM, 2011, 13 (08) :692-702
[38]   A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials [J].
Zhu, S. ;
Wu, Z. ;
Wang, W. ;
Wei, L. ;
Zhou, H. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (04) :761-776
[39]   Pathogenesis of non-alcoholic fatty liver disease [J].
Anty, Rodolphe ;
Gual, Philippe .
PRESSE MEDICALE, 2019, 48 (12) :1468-1483
[40]   Mitochondria in non-alcoholic fatty liver disease [J].
Simoes, Ines C. M. ;
Fontes, Adriana ;
Pinton, Paolo ;
Zischka, Hans ;
Wieckowski, Mariusz R. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2018, 95 :93-99